Related content

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

By Hesketh Paul   Younger Jerry   Sanz-Altamira Pedro   Hayden Melissa   Bushey Julie   Trainor Brian   Krentzin Michael   Nowd Peter   Arnaoutakis Konstantinos   Hesketh Ann  

Supportive Care in Cancer, Vol. 17, Iss. 8, 2009-08 ,pp. : 1065-1070

Springer Publishing Company

Access to resources Recommend Favorite

Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study

By Linot B.   Campone M.   Augereau P.   Delva R.   Abadie-Lacourtoisie S.   Nebout-Mesgouez N.   Capitain O.  

Journal of Neuro-Oncology, Vol. 117, Iss. 2, 2014-04 ,pp. : 253-259

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

By Saito H.   Yoshizawa H.   Yoshimori K.   Katakami N.   Katsumata N.   Kawahara M.   Eguchi K.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1067-1073

Oxford University Press

Access to resources Recommend Favorite

Fatigue in patients with prostate cancer receiving hormone therapy

By Stone P.   Hardy J.   Huddart R.   A'Hern R.   Richards M.  

European Journal of Cancer, Vol. 36, Iss. 9, 2000-06 ,pp. : 1134-1141

Elsevier

Access to resources Recommend Favorite

Surgical considerations in patients receiving neoadjuvant systemic therapy

By Chawla Akhil   Hunt Kelly K   Mittendorf Elizabeth A  

Future Oncology, Vol. 8, Iss. 3, 2012-03 ,pp. : 239-250

Future Medicine

Access to resources Recommend Favorite